Theriva Biologics (TOVX) Stock Price, News & Analysis

Company Overview

Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company's lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors. It also develops VCN-11 for treating solid tumors; SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage to prevent overgrowth and infection by pathogenic organisms, such Clostridioides difficile infection and vancomycin resistant Enterococci, and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. It has collaboration agreements with The University of Texas at Austin, Catalan Institute of Oncology, Fundació Privada Institut d'Investigacio Biomedica de Bellvitge, Saint Joan De Déu, and Massachusetts General Hospital, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.

Key Stats

• Today's Range: $1.34 to $1.42
• 50-Day Range: $1.05 to $1.61
• 52-Week Range: $0.96 to $12.28
• Volume: 18,963 shs
• Average Volume: 1.00 million shs
• Market Capitalization: $3.84 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.00
• Consensus Rating: Buy

Theriva Biologics Stock Analysis - MarketRank™

Theriva Biologics scored higher than 35% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Theriva Biologics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Theriva Biologics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Theriva Biologics is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Theriva Biologics is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Theriva Biologics has a P/B Ratio of 0.03. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.52% of the float of Theriva Biologics has been sold short.

Short Interest Ratio / Days to Cover

Theriva Biologics has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Theriva Biologics has recently increased by 22.41%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Theriva Biologics does not currently pay a dividend.

Dividend Growth

Theriva Biologics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.52% of the float of Theriva Biologics has been sold short.

Short Interest Ratio / Days to Cover

Theriva Biologics has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Theriva Biologics has recently increased by 22.41%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

News Sentiment

Theriva Biologics has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Theriva Biologics this week, compared to 0 articles on an average week.

Search Interest

1 people have searched for TOVX on MarketBeat in the last 30 days.

MarketBeat Follows

Only 1 people have added Theriva Biologics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Theriva Biologics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.05% of the stock of Theriva Biologics is held by insiders.

Percentage Held by Institutions

Only 6.17% of the stock of Theriva Biologics is held by institutions.

TOVX Stock Analysis - Frequently Asked Questions

How have TOVX shares performed this year?

Theriva Biologics' stock was trading at $1.65 on January 1st, 2025. Since then, TOVX shares have decreased by 16.4% and is now trading at $1.38.
View the best growth stocks for 2025 here.

How were Theriva Biologics' earnings last quarter?

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) issued its quarterly earnings results on Tuesday, November, 12th. The company reported ($6.81) EPS for the quarter, missing analysts' consensus estimates of ($6.25) by $0.56.

When did Theriva Biologics' stock split?

Theriva Biologics's stock reverse split before market open on Monday, August 26th 2024. The 1-25 reverse split was announced on Friday, August 16th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 23rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

How do I buy shares of Theriva Biologics?

Shares of TOVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Theriva Biologics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Theriva Biologics investors own include BIOLASE (BIOL), Jiuzi (JZXN), Daré Bioscience (DARE), Dermata Therapeutics (DRMA), Faraday Future Intelligent Electric (FFIE), Adial Pharmaceuticals (ADIL) and Aditxt (ADTX).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 5/03/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSEAMERICAN:TOVX
• CIK: 894158
• Web: therivabio.com
• Phone: (301) 417-4364
• Fax: 301-417-4367
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $6.00
• High Stock Price Target: $6.00
• Low Stock Price Target: $6.00
• Potential Upside/Downside: +334.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($33.06)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-18,350,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -76.12%
• Return on Assets: -48.54%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.67
• Quick Ratio: 2.67

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $54.22 per share
• Price / Book: 0.03

Miscellaneous

• Outstanding Shares: 2,780,000
• Free Float: 2,697,000
• Market Cap: $3.84 million
• Optionable: Not Optionable
• Beta: 1.22